Profiel
Michael Watson has held various director positions in different companies, including VaxEquity Ltd., Foundation for Innovative New Diagnostics, Meissa Vaccines, Inc., and Osivax SAS.
He is currently the Executive Chairman at VaxEquity Ltd.
and a Director at the Foundation for Innovative New Diagnostics, Meissa Vaccines, Inc., and Osivax SAS.
Actieve functies van Michael Watson
Bedrijven | Functie | Begin |
---|---|---|
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | Directeur/Bestuurslid | - |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | Directeur/Bestuurslid | 13-04-2021 |
VaxEquity Ltd.
VaxEquity Ltd. BiotechnologyHealth Technology VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. | Voorzitter | - |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | Directeur/Bestuurslid | 14-04-2022 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | Health Services |
Meissa Vaccines, Inc.
Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | Health Technology |
VaxEquity Ltd.
VaxEquity Ltd. BiotechnologyHealth Technology VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. | Health Technology |
Osivax SAS
Osivax SAS BiotechnologyHealth Technology Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France. | Health Technology |